Novartis Issues Over $3.7 Billion in New Notes
Ticker: NVSEF · Form: 6-K · Filed: Sep 18, 2024 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | 6-K |
| Filed Date | Sep 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $1,000,000,000, $850,000,000, $1,100,000,000, $750,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-issuance, financing, notes
Related Tickers: NVS
TL;DR
Novartis just dropped over $3.7B in new debt across multiple maturities.
AI Summary
Novartis AG, through its subsidiary Novartis Capital Corporation, announced the issuance of new notes on September 18, 2024. The issuance includes $1,000,000,000 in 3.800% Notes due 2029, $850,000,000 in 4.000% Notes due 2031, $1,100,000,000 in 4.200% Notes due 2034, and $750,000,000 in 4.700% Notes due 2054. These notes are being incorporated into Novartis AG's Registration Statement on Form F-3.
Why It Matters
This debt issuance provides Novartis with significant capital, potentially for funding operations, acquisitions, or research and development, impacting its financial flexibility and future growth strategies.
Risk Assessment
Risk Level: low — The filing is a routine debt issuance announcement by a large, established company, with no immediate negative indicators.
Key Numbers
- $3.7B — Total Debt Issued (Aggregate principal amount of all notes issued ($1B + $0.85B + $1.1B + $0.75B).)
- 3.800% — 2029 Notes Interest Rate (Coupon rate for the notes due in 2029.)
- 4.700% — 2054 Notes Interest Rate (Coupon rate for the notes due in 2054.)
Key Players & Entities
- Novartis AG (company) — Registrant
- Novartis Capital Corporation (company) — Issuer of notes
- $1,000,000,000 (dollar_amount) — Principal amount of 2029 Notes
- $850,000,000 (dollar_amount) — Principal amount of 2031 Notes
- $1,100,000,000 (dollar_amount) — Principal amount of 2034 Notes
- $750,000,000 (dollar_amount) — Principal amount of 2054 Notes
- September 18, 2024 (date) — Report date and issuance date
FAQ
What is the total aggregate principal amount of notes issued by Novartis Capital Corporation?
The total aggregate principal amount is $3,700,000,000, comprising $1,000,000,000 of 2029 Notes, $850,000,000 of 2031 Notes, $1,100,000,000 of 2034 Notes, and $750,000,000 of 2054 Notes.
What are the maturity dates for the newly issued notes?
The notes have maturities in 2029, 2031, 2034, and 2054.
What is the purpose of filing this Form 6-K?
This Form 6-K is filed in connection with the issuance of the new notes by Novartis Capital Corporation and for incorporation into Novartis AG's Registration Statement on Form F-3.
What are the interest rates for the different note issuances?
The interest rates are 3.800% for the 2029 Notes, 4.000% for the 2031 Notes, 4.200% for the 2034 Notes, and 4.700% for the 2054 Notes.
Which entity is directly issuing the notes?
Novartis Capital Corporation is issuing the notes.
Filing Stats: 350 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-09-18 16:38:44
Key Financial Figures
- $1,000,000,000 — ance by Novartis Capital Corporation of $1,000,000,000 aggregate principal amount of 3.800% No
- $850,000,000 — ue 2029 (the “2029 Notes”), $850,000,000 aggregate principal amount of 4.000% No
- $1,100,000,000 — ue 2031 (the “2031 Notes”), $1,100,000,000 aggregate principal amount of 4.200% No
- $750,000,000 — 2034 (the “2034 Notes”) and $750,000,000 aggregate principal amount of 4.700% No
Filing Documents
- tm2423681d8_6k.htm (6-K) — 11KB
- tm2423681d8_ex1-1.htm (EX-1.1) — 243KB
- tm2423681d8_ex4-1.htm (EX-4.1) — 79KB
- tm2423681d8_ex4-2.htm (EX-4.2) — 79KB
- tm2423681d8_ex4-3.htm (EX-4.3) — 76KB
- tm2423681d8_ex4-4.htm (EX-4.3) — 76KB
- tm2423681d8_ex4-5.htm (EX-4.5) — 25KB
- tm2423681d8_ex5-1.htm (EX-5.1) — 13KB
- tm2423681d8_ex5-2.htm (EX-5.2) — 48KB
- tm2423681d8_ex1-1img001.jpg (GRAPHIC) — 5KB
- tm2423681d8_ex5-2img001.gif (GRAPHIC) — 2KB
- 0001104659-24-100991.txt ( ) — 662KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 18, 2024 Novartis AG By: /s/ Daniel Weiss Name: Daniel Weiss Title: Authorized Signatory